Storage Duration Of Red Blood Cells And Risk Of Developing Acute Lung Injury In Patients With Sepsis

Author(s):  
David R. Janz ◽  
Tatsuki Koyama ◽  
Zhiguo Zhao ◽  
Benjamin Cripps ◽  
Julie A. Bastarache ◽  
...  
2013 ◽  
Vol 3 (1) ◽  
pp. 33 ◽  
Author(s):  
David R Janz ◽  
Zhiguo Zhao ◽  
Tatsuki Koyama ◽  
Addison K May ◽  
Gordon R Bernard ◽  
...  

Transfusion ◽  
2011 ◽  
Vol 51 (12) ◽  
pp. 2549-2554 ◽  
Author(s):  
Christopher C. Silliman ◽  
Ernest E. Moore ◽  
Marguerite R. Kelher ◽  
Samina Y. Khan ◽  
Lauren Gellar ◽  
...  

Transfusion ◽  
2014 ◽  
Vol 54 (10) ◽  
pp. 2425-2430 ◽  
Author(s):  
Litchia L. Weber ◽  
Laura D. Roberts ◽  
Joseph D. Sweeney

1998 ◽  
Vol 101 (7) ◽  
pp. 1458-1467 ◽  
Author(s):  
C C Silliman ◽  
N F Voelkel ◽  
J D Allard ◽  
D J Elzi ◽  
R M Tuder ◽  
...  

Blood ◽  
2009 ◽  
Vol 113 (9) ◽  
pp. 2079-2087 ◽  
Author(s):  
Marguerite R. Kelher ◽  
Tomhiko Masuno ◽  
Ernest E. Moore ◽  
Sagar Damle ◽  
Xianzhong Meng ◽  
...  

Transfusion-related acute lung injury (TRALI) is the leading cause of transfusion death. We hypothesize that TRALI requires 2 events: (1) the clinical condition of the patient and (2) the infusion of antibodies against MHC class I antigens or the plasma from stored blood. A 2-event rat model was developed with saline (NS) or endotoxin (LPS) as the first event and the infusion of plasma from packed red blood cells (PRBCs) or antibodies (OX18 and OX27) against MHC class I antigens as the second event. ALI was determined by Evans blue dye leak from the plasma to the bronchoalveolar lavage fluid (BALF), protein and CINC-1 concentrations in the BALF, and the lung histology. NS-treated rats did not evidence ALI with any second events, and LPS did not cause ALI. LPS-treated animals demonstrated ALI in response to plasma from stored PRBCs, both prestorage leukoreduced and unmodified, and to OX18 and OX27, all in a concentration-dependent fashion. ALI was neutrophil (PMN) dependent, and OX18/OX27 localized to the PMN surface in vivo and primed the oxidase of rat PMNs. We conclude that TRALI is the result of 2 events with the second events consisting of the plasma from stored blood and antibodies that prime PMNs.


Shock ◽  
2006 ◽  
Vol 25 (Supplement 1) ◽  
pp. 21
Author(s):  
T. Masuno ◽  
E. Moore ◽  
S. Damle ◽  
A. Cheng ◽  
M. Kelher ◽  
...  

2012 ◽  
Vol 215 (3) ◽  
pp. S49-S50
Author(s):  
John R. Stringham ◽  
Ernest E. Moore ◽  
Michael Ellison ◽  
Marguerite R. Kelher ◽  
Kirk C. Hansen ◽  
...  

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. SCI-48-SCI-48 ◽  
Author(s):  
Christopher C. Silliman

Abstract Abstract SCI-48 Stored packed red blood cells (PRBCs) have been implicated in increased morbidity and mortality in critically ill patients, patients requiring cardiothoracic surgery, and injured patients following blunt and/or penetrating trauma. Lipids are generated during the routine storage of cellular blood components and have been implicated in transfusion-related acute lung injury (TRALI) and postinjury multiple organ failure (MOF). These lipids are comprised of two classes, as denoted by their retention times on normal-phase HPLC: 1) nonpolar lipids, including arachidonic acid, 5-hydroxy-eicosotetranoic acid (HETE), 12-HETE, 15-HETE, and 5-oxo-eicosotetranoic acid (5-oxo-ETE); and 2) a mixture of lysophosphatidylcholines (lyso-PCs), including stearoyl-, oleoyl-, or palmitoyl-lyso-PCs as well as C16 or C18 lyso-platelet activating factor. Importantly, all of these lipids were identified by quadrupole LC/MS/MS. The former are derived from red blood cells, because they are generated during the routine storage of prestorage leuko- and platelet-reduced PRBCs, while the latter are platelet-derived, and are generated during storage of platelet concentrates (PC) and unmodified PRBCs but not leukocyte-reduced PRBCs (LR-PRBCs). Generation of the nonpolar lipids requires an active phospholipase, such as peroxiredoxin-6, which accumulates during PRBC and LR-PRBC storage and appears to be active and T-phosphorylated. The nonpolar lipids do not accumulate during PC storage. These lipids are released into the plasma fraction of the stored component and have been shown to: 1) prime the polymorphonuclear leukocytes (PMN) oxidase; 2) activate primed PMNs; and 3) serve as the second event in a two-event model of TRALI in both rodents and sheep. This lipid priming of PMNs occurs through activation of specific receptors, for example G2A, for lyso-PCs, and causes activation of G-protein-linked cellular receptor, G-protein release, and stimulation of kinase cascades. This results in translocation of the cytosolic oxidase components and a change from a resting PMN phenotype to a hyperactive, adherent phenotype. Conversely, stored PRBCs have also been implicated in MOF. However, acute lung injury does not occur until 72 hours postinjury, implicating PRBCs as a first event(s). The nonpolar lipids that accumulate during routine storage activate primary human pulmonary microvascular endothelial cells (HMVECs) and primary human liver sinusoidal endothelial cells (LSECs), as quantified by increased surface expression of intercellular adhesion molecule-1 (ICAM-1) and the synthesis and release of chemokines, for example IL-8. This proinflammatory activation results in PMN adherence, and such HMVEC activation occurs through activation of the BLT2 receptor and activation of a PKC-dependent kinase cascade. Stored PRBCs (day 42) may serve as the first event in a two-event rodent model of acute lung injury. We conclude that lipids generated during the routine storage of cellular blood components have proinflammatory effects in vitro and in vivo, which may explain some of the adverse events of transfusion, including TRALI and postinjury MOF, and that inhibition and avoidance of these compounds may make transfusions safer. Further research is already under way in several prospective trials, including: 1) Age of Blood Components transfused in the PICU (ABC-PICU); 2) red cell storage duration and outcomes in cardiac surgery at the Cleveland Clinic; 3) Red Cell Storage duration Study (RECESS); and 4) the Age of Blood Evaluation trial (ABLE). Disclosures: Silliman: Pall Corporation: Honoraria, Research Funding.


Sign in / Sign up

Export Citation Format

Share Document